We previously found that a lectin, Sambucus sieboldiana agglutinin (SSA), bound to a2,6-sialylated glycan epitopes on transferrin and inhibited anti-transferrin antibody binding to the antigen in ELISA (SSA inhibition). Here we report that SSA inhibition is applicable to immunohistochemistry, localizing a2,6-sialylated transferrin in the liver. Immunohistochemistry using anti-transferrin polyclonal antibody revealed that transferrin was detected in hepatocytes near interlobular veins. Addition of SSA lectin markedly attenuated the staining. Sialidase treatment of a liver section abolished SSA binding and concomitantly cancelled SSA inhibition, suggesting that SSA binding to glycan epitopes on the section was essential for the inhibition. To examine the importance of proximity between antigen epitopes and SSA-binding (glycosylation) sites, we prepared two anti-peptide antibodies against partial amino acid sequences of transferrin. One antibody (Tf-596Ab) is against a peptide sequence, Cys596-Ala614, which is proximal to N-glycosylation sites (Asn-432 and Asn-630). The other (Tf-120Ab) is against a peptide sequence, Val120-Cys137, distal to the sites. The staining signals of Tf-596Ab were reduced by the addition of SSA, whereas those of Tf-120Ab were reduced only a little. This result suggests that proximity of the antigen epitope to SSA binding sites is critical for SSA inhibition in immunohistochemistry.
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Human transferrin (Tf), an iron carrier, is a serum glycoprotein biosynthesized in the liver. In hepatocytes, a nascent polypeptide of Tf is biosynthesized in endoplasmic reticulum and then glycosylated at asparagine residues, Asn-432 and Asn-630. A large part of N-linked oligosaccharide is extensively trimmed in endoplasmic reticulum. Further glycosylations such as galactosylation and sialylation occur in the Golgi apparatus and trans-Golgi network (1) . We previously demonstrated that a2,6-sialylation is efficiently catalysed by a soluble form of a2,6-sialyltransferase that has been cleaved or processed by BACE1 (beta-site amyloid precursor protein-cleaving enzyme-1) protease (2, 3) . Thus Tf having Siaa2,6Gal residues at the nonreducing termini of N-glycans is biosynthesized and then secreted from the liver into blood. During blood circulation, 'aged' Tf have lost sialic acid residues, generating asialo-Tf. The asialo-Tf is captured by an asialo-glycoprotein (galactose-binding) receptor on hepatocytes, and the binding complex is internalized for subsequent lysosomal degradation (4) . In lysosomes, glycans of asialo-Tf are trimmed by glycosidases such as bgalactosidase and b-N-acetylhexosaminidase (5). Thus glycans on Tf are metabolized in the hepatocytes, yielding various glycan isoforms. It is noted that each glycan isoform is hard to distinguish by conventional immunohistochemistry, because most anti-Tf antibodies recognize the protein portion of Tf regardless of its glycan-isoform. Lectins as glycan-specific probes are useful for detecting glycan epitopes, but they bind to glycans regardless of core proteins (6) .
We previously found that Sambucus sieboldiana agglutinin (SSA) lectin inhibited antigenantibody reactions when the antigen carries a2,6sialylated glycans (SSA inhibition) (7) . For instance, SSA inhibited binding of anti-Tf antibody to purified a2,6-sialylated Tf. Removal of sialic acid residues on Tf by sialidase completely abolished the inhibition, suggesting that binding of SSA to sialyla2,6galactose epitopes on Tf itself is essential for the inhibition. This finding was successfully applied to immunological assays such as enzyme-linked immunosorbent assay (ELISA) and latex immunoagglutination assay, resulting in highthroughput quantification of a2,6-sialylated Tf in cerebrospinal fluid (7) . In this study, we applied SSA inhibition to visualize a2,6-sialylated Tf on a liver section.
Materials and Methods
Tf isoforms and antibodies Serum Tf was purchased from Sigma-Aldrich (St. Louis, MO). Purified Tf was treated with sialidase (Nacalai Tesque, Japan) to remove sialyl residues on N-glycans, generating asialo-Tf (8) . Anti-Tf polyclonal antibodies were purchased from DAKO Co., Ltd. (Glostrup, Denmark). For preparation of anti-peptide antibodies, peptide antigens containing amino acid sequence VKKDSGFQMNQLRGKKSC (Val120-Cys137) or CHLARAPNHAVVTRKDKEA (Cys596-Ala614) were chemically synthesized. Each peptide was conjugated with keyhole limpet haemocyanin and then the conjugates were immunized to rabbits. Antipeptide antibodies were purified by antigen-affinity column chromatography (2) . All antibodies used were treated with 1 mM sodium periodate to oxidize the exocyclic glycerol side chain of sialic acid (9) , thus abolishing SSA epitopes on the antibodies.
Immunoblotting and lectin blotting Immunoblotting was optimized as described before (10). Samples were dissolved in Laemmli sample buffer, boiled for 3 min, and loaded onto sodium dodecyl sulfate (SDS)-polyacrylamide gels (SuperSep Ace; Wako Pure Chemical Industries, Japan). After SDS-PAGE, the proteins were transferred to a nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA). The membrane was blocked in 3% skim milk, incubated with Tf-polyAb, Tf-120Ab or Tf-596Ab. The membrane was further incubated with a horseradish peroxidase-labelled second antibody (anti-rabbit IgG from Promega, Madison, WI), and developed using SuperSignal West Dura Extended Duration Substrate (Pierce Biotechnology, Rockford, IL). For lectin blotting, the protein-transferred membrane was blocked in 1% BSA, incubated with a biotinylated SSA (Seikagaku Corporation, Japan) followed by a horseradish peroxidase-labelled streptavidin (Takara, Japan), and developed. For peptide inhibition assay, anti-peptide antibodies were pre-incubated with either Val120-Cys137 or Cys596-Ala614 peptide overnight at 4 C.
Immunohistochemistry
Liver tissue was fixed in phosphate-buffered 15% formalin solution and embedded in paraffin. A pair of mirror image sections (5-mm thick), exposing opposite sliced surfaces, were incubated with or without SSA (40 mg/ml) overnight at 4 C. The sections were then stained with Tf-polyAb (1:1000), Tf-120Ab (1:100) or Tf-596Ab (1:100) overnight at 4 C followed by biotinylated anti-rabbit IgG (1:200). Bound antigens were visualized with Histofine reagent (Nichirei, Japan). For sialidase treatment, tissue sections were incubated with sialidase for 6 h at 37 C. After washing with phosphatebuffered saline, the sections were then incubated with a biotinylated SSA followed by a horseradish peroxidase-labelled streptavidin, and developed. The sialidase-treated sections were subjected to SSA inhibition assay as described above. For inhibition assay, Tf120Ab and Tf-596Ab were pre-incubated with either Val120-Cys137 or Cys596-Ala614 peptide. Methyl Green is used for nuclear counterstaining.
Results

SSA lectin-dependent inhibition of immunohistochemical antigen-antibody reactions
Human serum Tf is biosynthesized in the liver and then secreted into blood. Immunohistochemistry using polyclonal antibody against Tf (Tf-polyAb) revealed that some hepatocytes near interlobular vein were stained by Tf-polyAb ( Fig. 1A ; also see Fig. 5 ). Pre-treatment of the liver section with SSA lectin significantly reduced the Tf signals (Fig. 1A) . Granular signals were well attenuated, whereas some diffuse ones were retained. The result suggested that SSA lectin partially inhibited the binding of Tf-polyAb to Tf on the liver section (SSA inhibition). Next we examined whether or not SSA inhibition required sialyla2,6galactose residues, binding epitopes for SSA. To localize SSA epitopes, a liver section was stained by using biotinylated SSA and HRP-labelled streptavidin. The SSA staining reveals that some hepatocytes near interlobular vein were stained by SSA (Fig. 1B) . The SSA signals were abolished by sialidase treatment, suggesting that sialidase efficiently removed sialic acid residues from the liver section, thus destroying SSA epitopes (Fig. 1B) . Next, the sialidase-treated sections were subjected to SSA inhibition assay. On the sialidase-treated sections, SSA showed subtle effect on Tf-polyAb binding to Tf (Fig. 1C) . The result suggests that SSA inhibition requires the binding of SSA to sialic acid-containing epitopes on the liver section.
Preparation of anti-peptide antibodies and their reactivity against Tf isoforms
We further characterized SSA inhibition using sitedirected anti-peptide antibodies. Tf has two N-glycosylation sites at Asn-432 and Asn-630 in its amino acid sequence ( Fig. 2A) . These asparagine residues are mapped on the C-lobe at carboxy-terminal domain and are close to each other on a 3D-model (Fig. 2B) . We prepared two anti-peptide antibodies against Tf; one antibody (Tf-596Ab) was prepared against a peptide sequence, Cys596-Ala614, which was close to two N-glycosylation sites (Fig. 2) . The other antibody (Tf-120Ab) was prepared against a peptide sequence, Val120-Cys137, which is located far from N-glycosylation sites on the N-lobe (Fig. 2) . Tf-120Ab and Tf-596Ab were raised against chemically synthesized peptides with an expectation that antibodies recognized antigen peptide sequence and equally reacted with various glycoforms of Tf. Indeed, like TfpolyAb, both Tf-120Ab and Tf-596Ab reacted with crude serum Tf, purified a2,6-sialylated Tf and asialo-Tf on immunoblots (Fig. 3A and B) , indicating that Tf-120Ab and Tf-596Ab reacted with Tfs regardless of their glycoforms. The mobility of asialo-Tf on the SDS-PAGE proceeded faster than that of a2,6-sialylated-Tf and its loss of sialic acid was confirmed by SSA lectin blotting (Fig. 3C) .
The antigen peptides inhibit antigenantibody reaction Next we examined whether Tf-120Ab and Tf-596Ab specifically recognize target sequences on Tfs. Antigenantibody interaction was competed using the antigen peptides as inhibitors in immunoblotting. A peptide of Val120-Cys137 inhibited Tf-120Ab binding to crude serum Tf, purified a2,6-sialylated Tf and asialo-Tf (Fig. 4A) , whereas the peptide did not inhibit Tf-596Ab biding to the glycoforms (Fig. 4B ). In contrast, a peptide of Cys596-Ala614 inhibited Tf-596Ab probe: Tf-pAb 
Asn-432
Asn-630 Visualization of a2,6-sialylated transferrin in the liver binding to Tf glycoforms, but did not inhibit Tf-120Ab binding (Fig. 4) . These results suggest that Tf-120Ab and Tf-596Ab specifically recognize each antigen peptide sequence on Tf isoforms.
Proximity of antigen epitopes to glycans affects SSA inhibition Anti-peptide antibodies, Tf-120Ab and Tf-596Ab, were subjected to SSA inhibition assay in immunohistochemistry. In the absence of SSA, both anti-peptide antibodies stained some hepatocytes near interlobular vein, but not hepatocytes near central veins (Fig. 5) . In the presence of SSA, Tf-120Ab staining was subtly reduced by the addition of SSA (Fig. 5A) , whereas Tf-596Ab staining was markedly reduced (Fig. 5B) . Thus SSA subtly inhibited Tf-120Ab, which specifically recognized the peptide sequence distal to the glycosylation sites. In contrast, SSA remarkably inhibited Tf-596Ab recognizing the peptide sequence proximal to the glycosylation sites. These results suggest that proximity between the antigen epitopes and N-glycosylation sites is important for SSA inhibition. Fig. 3 Binding of anti-Tf antibodies to serum Tf, a2,6-sialylated Tf and asialo-Tf. Serum proteins (serum), purified a2,6-sialylated Tf (Tf) and asialo-Tf were subjected to SDS-PAGE followed by silver staining (A) or immunoblotting (B). Antibodies used for immunostaining were Tf-polyAb, Tf-120Ab and Tf-596Ab. A blot was also stained with SSA (C).
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Discussion
In this study, we demonstrate that SSA lectin inhibits Tf-polyAb binding to a2,6-sialylated Tf on a liver section (SSA inhibition), which is applied to visualizing the localization of the glycoform in the liver. This is the first immunohistochemical demonstration of localizing a particular glycoform in a tissue section. It is noted that both SSA-inhibitable and non-inhibitable Tf signals are localized near interlobular veins (Figs 1 and 5) . The result appears to be consistent with the previous findings that hepatocytes near interlobular veins were different from hepatocytes around central veins in their enzyme contents for metabolism of glucose, lipids, urea and so forth (11) , and that hepatocytes near interlobular vein preferentially produced sialoglycoproteins such as haptoglobin, a1-acid glycoprotein, a2-macroglobulin and fibrinogen (12) .
SSA inhibition appears to require binding of SSA to Siaa2,6Gal epitopes on N-glycans of Tf, because removal of sialic acid by neuraminidase treatment markedly attenuated SSA inhibition signals on the liver section (Fig. 1) . This result is consistent with our previous observation, in which removal of sialic acid from purified a2,6-sialylated Tf abolished SSA inhibition in biochemical systems like ELISA (7) . The biochemical analysis also revealed that SSA partially inhibited antigenantibody reaction even with purified a2,6-sialylated Tf, i.e. maximal inhibition in ELISA and automated latex immunoagglutination (ALI) assay was 60 and 77%, respectively. It is possible that the partial inhibition is attributed to replacement of SSA at the step of antibody reaction in immunohistochemistry and ELISA. In ALI, however, the presence of a large excess of SSA together with antibody in a flow cell system did not increase the maximal inhibition, suggesting that SSA replacement by the antibody is less likely for the partial inhibition.
Molecular weight of SSA is reported to be $40 kDa and the lectin forms tetramer ($160 kDa complex), the size of which may partly account for hindrance of many antigen epitopes on Tf. The speculation may be supported by the observation that TJA-I lectin ($70 kDa) and RCA lectin ($60 kDa) inhibited Tf antibody binding to a2,6-sialylated Tf and asialo-Tf by only 11 and 30%, respectively, in ELISA (unpublished observation). In addition to the size of lectin, many other factors such as the number of glycans and molecular size of antigens and relative affinities of lectins and antibodies would also affect the lectin inhibition. Systemic analysis using various lectins and antigens will be needed for further characterization of lection inhibition in the future.
Partial inhibition of antibody binding to an antigen was also reported for Lens culinaris agglutinin (LCA) lectin, recognizing core fucose (13) . The lectin inhibited monoclonal antibody binding to fucosylated alphafetoprotein, an early marker of hepatocellular carcinoma (14, 15) . It was noted, however, that LCA lectin inhibited only 2 out of 30 monoclonal antibodies; one was inhibited by 36% and the other was 59%. Suzuki et al. speculated that LCA bound to the core fucose and sterically hindered neighboring antigen epitopes recognized by the two monoclonal antibodies. It is notable in this study that SSA lectin inhibited even polyclonal Tf-polyAb binding, suggesting that SSA complexed with Tf glycans was flexible enough to hinder a large part of antigen epitopes on Tf. This speculation led us to examine SSA inhibition using site-directed peptide antibodies; one was Tf-596Ab against a peptide sequence, Cys596-Ala614, which was proximal to N-glycosylation sites, and the other was Tf-120Ab against a peptide sequence, Val120-Cys137, which was distal to N-glycosylation sites (Fig. 2) . SSA inhibited binding of Tf-596Ab but did Tf-120Ab only a little (Fig. 5) , suggesting that proximity of the antigen epitope to N-glycans is important for SSA inhibition. SSA complexed with the N-glycans may inhibit majority of Tf-polyAb clones, but it may not inhibit some antibody clones that recognize 'distal' antigen epitopes. This may explain why SSA partially inhibits Tf-polyAb signals in immunohistochemical and biochemical assays. We tried to establish ELISA using Tf-120Ab or Tf-596Ab for quantitative comparison of their susceptibility to SSA inhibition, but it was unsuccessful. The antibodies may have too low affinity to establish ELISA or some denaturation of Tf may be required for exposing antigen epitopes.
Tf-596Ab should include antibody clones that recognize the proximal peptide sequence, Cys596-Ala614, but the antibody still shows residual signals on the liver sections in the presence of SSA. This is possibly due to the presence of other glycoforms such as high mannose-type glycoforms in the biosynthetic pathway and asialo-forms in the degradation pathway, which should generate the residual signals on the liver section. Visualization of a2,6-sialylated transferrin in the liver SSA inhibition was applied to detect a2,6-sialylated Tf in immunohistochemical and biochemical assays. It is tempting to speculate that SSA inhibition would be applicable for visualizing other a2,6-sialylated antigens by immunohistochemistry. For instance, carcinoembryonic antigen (CEA) purified from liver metastases of colon adenocarcinoma expresses N-glycans carrying a2,6sialyl residues, whereas a normal counterpart of CEA (NFA-2) does those carrying a2,3sialyl residues (16, 17) . The former glycan epitope associated with tumorigenesis is recognized by SSA, SNA and TJA-I lectins. Indeed, TJA-I showed expression of a2,6sialyl epitopes in colonic adenocarcinoma, but neither normal mucosa nor benign adenoma. It should be noted, however, that TJA-I reacts with various a2,6sia-lylated glycoproteins other than a2,6sialylated CEA. SSA inhibition assay may localize a2,6sialylated CEA on colon cancer sections.
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